Pleomorphic adenoma overview

Jump to navigation Jump to search

Pleomorphic adenoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pleomorphic adenoma from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT scan

MRI

Echocardiography and Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pleomorphic adenoma overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pleomorphic adenoma overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pleomorphic adenoma overview

CDC on Pleomorphic adenoma overview

Pleomorphic adenoma overview in the news

Blogs on Pleomorphic adenoma overview

Directions to Hospitals Treating Pleomorphic adenoma

Risk calculators and risk factors for Pleomorphic adenoma overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Pleomorphic adenoma also known as ("Benign mixed tumor of the salivary glands") is a benign neoplastic tumor of the salivary glands. It is the most common type of salivary gland tumor and the most common tumor of the parotid gland. In 1874, pleomorphic adenoma was first described by Minssen in a monograph named Ahlbom's. Later Mark and Dahlenfors in 1986 and Bullerdiek et al. in 1987 found some clonal chromosome abnormalities related to pleomorphic adenoma, with a majority of aberrations involving 8q12. Pleomorphic adenoma can be classified on the basis of the histological appearance into 4 subgroups. Subgroup 1 is the classical pleomorphic adenoma with a stroma content of 30-50%, subgroup 2 has a stroma content of 80%, subgroup 3 has a poor stroma content of 20-30%, subgroup 4 has also a poor stroma content (6%). Pleomorphic adenoma shows chromosomal transposition mainly involving PLAG1 and HMGA2. Pleomorphic adenoma's are usually firm, mobile, well demarcated and encapsulated on gross apperance. On microscopy it is characterized by both epithelial elements and stromal matrix which can be either hyaline, myxoid or cartilaginous. The incidence of Pleomorphic adenoma is approximately 2-3.5 cases per 100,000 population. Females are predominantly affected by Pleomorphic adenoma than males. The various risk factors for the development of pleomorphic adenoma are prior irradiation to head and neck, working in rubber, asbestos industries. The most common presentation is a painless, slow growing and single palpable mass. Pleomorphic adenoma is usually asymtomatic but some people present with dysphagia, hoarseness, difficulty with chewing. MRI is the imaging modality of choice for pleomorphic adenoma. Total parotidectomy is the mainstay of treatment for pleomorphic adenoma. The complications of parotidectomy include haematoma or haemorrhage, facial nerve palsy, frey's syndrome. The prognosis of pleomorphic adenoma is excellent after complete surgical excision.

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Xyz from Other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

References


Template:WikiDoc Sources